Stable Isotopes Product Detail
Home Stable Isotopes CS-T-97557

Dolutegravir Sodium Salt-d6

Chemical Properties and Information

Product Code: CS-T-97557 Stable Isotopes
Dolutegravir Sodium Salt-d6
API Family
--
Product Code
CS-T-97557

Dolutegravir Sodium Salt-d6

Stable Isotopes
Stock Status: : Enquire Live

CAT No.
CS-T-97557
CAS No.
--
Molecular Formula
C20H12D6F2N3NaO5
Molecular Weight
447.4
Login to view price
There is no hazardous surcharge associated with this product.
There is no packaging charge associated with this product.
For Research Purposes only. Not for Personal use.
All compounds supplied are strictly intended for laboratory, research, analytical, and scientific use only. They are not meant for human consumption, therapeutic use, or any form of clinical application.
CAS No.
-
Product Code
CS-T-97557
M.F.
C20H12D6F2N3NaO5
M.W.
447.4
Category
Stable Isotopes
Storage Condition
Refer MSDS for complete information.
IUPAC Name
Dolutegravir Sodium Salt-d6
References
"Kobayashi, M. et al. Antimicrob Agents Chemother., 55, 813 (2011); Garrido, C. et al.: Antiviral, Res., 90, 164 (2011); Lenz, J.C.C. et al.: Exp. Opin. Invest. Drugs, 20, 537 (2011)"
Synonyms
"Dolutegravir sodium-d6; GSK 1349572A-d6; N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide Sodium Salt-d6"
Application Notes
"Dolutegravir Sodium Salt-d6, is the labeled analogue of Dolutegravir Sodium Salt (D528805), a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector."
Hazard Compound
Refer MSDS for complete information.
Overview
"Dolutegravir Sodium Salt-d6, is the labeled analogue of Dolutegravir Sodium Salt (D528805), a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector."
Downloading MSDS…
Quick Enquiry
Tell us what you need
Quote Basket
Selected RFQ Items
Your RFQ basket is empty. Add a product block or copy a guided requirement here.